Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK146D1 in advanced solid tumors
NCT07067567Phase 1Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2025
- Primary completion
- Nov 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AK146D1 in solid tumor (advanced stage), sponsored by Akeso, Inc. Primary endpoints: Dose Limiting Toxicities at 3 weeks and Adverse Events at 90 days. Started Aug 2025; status: recruiting.
02
Drugs
AK146D1
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07067567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07067567.